Travere (TVTX) Q2 2025 Earnings Call Summary
During Travere's second-quarter earnings call on August 6, 2025, CEO Eric Dube highlighted strong performance driven by FILSPARI in the treatment of IgA nephropathy. The company emphasized growing physician adoption and strategic initiatives to establish FILSPARI as foundational therapy for rare kidney diseases.
Tickers: $TVTX
Topics: clinical_development pharmaceuticals rare_kidney_disease